Charles River Laboratories (CRL) Tops Q3 EPS by 9c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Far-left party wins Berlin election, pledging to nationalise housing
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
Charles River Labs (CRL) PT Raised to $250 at Jefferies
November 3, 2022 8:14 AM EDTJefferies analyst David Windley raised the price target on Charles River Labs (NYSE: CRL) to $250.00 (from $240.00) while maintaining a Buy rating.
The analyst commented, "In broad strokes, the composition of CRL's strong report was as we expected in our upgrade. Consolidated... More
Charles River Laboratories (CRL) Announces Avian Vaccine Divestiture
November 2, 2022 7:21 AM EDTCharles River Laboratories (NYSE: CRL) announced that it has signed a definitive agreement to divest its Avian Vaccine business for approximately $170 million in cash with potential contingent payments of up to an additional $30 million, subject to certain closing adjustments.
The Avian... More
